{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:06:28Z","timestamp":1790899588600,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,1,24]],"date-time":"2015-01-24T00:00:00Z","timestamp":1422057600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00705-015-2333-2","type":"journal-article","created":{"date-parts":[[2015,1,23]],"date-time":"2015-01-23T18:43:00Z","timestamp":1422038580000},"page":"1125-1130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The sero-prevalence of anti-adenovirus\u00a05 neutralizing antibodies is independent of a chronic hepatitis B carrier state\u00a0in China"],"prefix":"10.1007","volume":"160","author":[{"given":"Dao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Hennequi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexei","family":"Elvachev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Menguy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Silvestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DeMin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Inchausp\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,24]]},"reference":[{"issue":"3","key":"2333_CR1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.coi.2011.03.006","volume":"23","author":"CS Rollier","year":"2011","unstructured":"Rollier CS, Reyes-Sandoval A, Cottingham MG, Ewer K, Hill AV (2011) Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol 23(3):377\u2013382. doi: 10.1016\/j.coi.2011.03.006","journal-title":"Curr Opin Immunol"},{"issue":"9","key":"2333_CR2","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1586\/erv.11.88","volume":"10","author":"JD Bassett","year":"2011","unstructured":"Bassett JD, Swift SL, Bramson JL (2011) Optimizing vaccine-induced CD8(+) T-cell immunity: focus on recombinant adenovirus vectors. Expert Rev Vaccines 10(9):1307\u20131319. doi: 10.1586\/erv.11.88","journal-title":"Expert Rev Vaccines"},{"key":"2333_CR3","first-page":"S55","volume":"58","author":"P Martin","year":"2013","unstructured":"Martin P, Dubois C, Jacquier E, Evlachev A, Boukhebza H, Dion S, Mancini-Bourgine M, Godon O, Findeli A, Schlesinger Y, Brandely R, Marchand JB, Menguy T, Silvestre N, Schirmbeck R, Michel M, Inchauspe G (2013) A multivalent adenovirus-based immunotherapeutic for treatment of chronic hepatitis B induces broad, robust and polyfunctional T cells in naive and HBV tolerant mice. J Hepatol 58:S55\u2013S56","journal-title":"J Hepatol"},{"issue":"4","key":"2333_CR4","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","volume":"28","author":"TC Mast","year":"2010","unstructured":"Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, Novitsky V, Mbewe B, Pitisuttithum P, Schechter M, Vardas E, Wolfe ND, Aste-Amezaga M, Casimiro DR, Coplan P, Straus WL, Shiver JW (2010) International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28(4):950\u2013957. doi: 10.1016\/j.vaccine.2009.10.145","journal-title":"Vaccine"},{"issue":"22","key":"2333_CR5","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1016\/j.vaccine.2011.03.042","volume":"29","author":"C Sun","year":"2011","unstructured":"Sun C, Zhang Y, Feng L, Pan W, Zhang M, Hong Z, Ma X, Chen X, Chen L (2011) Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China. Vaccine 29(22):3837\u20133841. doi: 10.1016\/j.vaccine.2011.03.042","journal-title":"Vaccine"},{"issue":"9","key":"2333_CR6","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/jmv.23325","volume":"84","author":"B Yu","year":"2012","unstructured":"Yu B, Zhou Y, Wu H, Wang Z, Zhan Y, Feng X, Geng R, Wu Y, Kong W, Yu X (2012) Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China. J Med Virol 84(9):1408\u20131414. doi: 10.1002\/jmv.23325","journal-title":"J Med Virol"},{"issue":"6","key":"2333_CR7","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/jmv.23546","volume":"85","author":"S Zhang","year":"2013","unstructured":"Zhang S, Huang W, Zhou X, Zhao Q, Wang Q, Jia B (2013) Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults. J Med Virol 85(6):1077\u20131084. doi: 10.1002\/jmv.23546","journal-title":"J Med Virol"},{"issue":"5","key":"2333_CR8","doi-asserted-by":"crossref","first-page":"e37532","DOI":"10.1371\/journal.pone.0037532","volume":"7","author":"Q Liu","year":"2012","unstructured":"Liu Q, Nie J, Huang W, Meng S, Yuan B, Gao D, Xu X, Wang Y (2012) Comparison of two high-throughput assays for quantification of adenovirus type 5 neutralizing antibodies in a population of donors in China. PLoS one 7(5):e37532. doi: 10.1371\/journal.pone.0037532","journal-title":"PLoS one"},{"issue":"3","key":"2333_CR9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00705-013-1828-y","volume":"159","author":"L Jian","year":"2014","unstructured":"Jian L, Zhao Q, Zhang S, Huang W, Xiong Y, Zhou X, Jia B (2014) The prevalence of neutralising antibodies to chimpanzee adenovirus type 6 and type 7 in healthy adult volunteers, patients with chronic hepatitis B and patients with primary hepatocellular carcinoma in China. Arch Virol 159(3):465\u2013470. doi: 10.1007\/s00705-013-1828-y","journal-title":"Arch Virol"},{"issue":"11","key":"2333_CR10","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/JCM.41.11.5046-5052.2003","volume":"41","author":"MC Sprangers","year":"2003","unstructured":"Sprangers MC, Lakhai W, Koudstaal W, Verhoeven M, Koel BF, Vogels R, Goudsmit J, Havenga MJ, Kostense S (2003) Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 41(11):5046\u20135052","journal-title":"J Clin Microbiol"},{"issue":"1","key":"2333_CR11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1089\/aid.2008.0212","volume":"25","author":"CD Harro","year":"2009","unstructured":"Harro CD, Robertson MN, Lally MA, O\u2019Neill LD, Edupuganti S, Goepfert PA, Mulligan MJ, Priddy FH, Dubey SA, Kierstead LS, Sun X, Casimiro DR, DiNubile MJ, Shiver JW, Leavitt RY, Mehrotra DV (2009) Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS Res Human Retroviruses 25(1):103\u2013114. doi: 10.1089\/aid.2008.0212","journal-title":"AIDS Res Human Retroviruses"},{"issue":"9653","key":"2333_CR12","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","volume":"372","author":"SP Buchbinder","year":"2008","unstructured":"Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. The Lancet 372(9653):1881\u20131893. doi:10.1016\/s0140-6736(08)61591-3","journal-title":"The Lancet"},{"issue":"10","key":"2333_CR13","doi-asserted-by":"crossref","first-page":"e25868","DOI":"10.1371\/journal.pone.0025868","volume":"6","author":"C Tamminga","year":"2011","unstructured":"Tamminga C, Sedegah M, Regis D, Chuang I, Epstein JE, Spring M, Mendoza-Silveiras J, McGrath S, Maiolatesi S, Reyes S, Steinbeiss V, Fedders C, Smith K, House B, Ganeshan H, Lejano J, Abot E, Banania GJ, Sayo R, Farooq F, Belmonte M, Murphy J, Komisar J, Williams J, Shi M, Brambilla D, Manohar N, Richie NO, Wood C, Limbach K, Patterson NB, Bruder JT, Doolan DL, King CR, Diggs C, Soisson L, Carucci D, Levine G, Dutta S, Hollingdale MR, Ockenhouse CF, Richie TL (2011) Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PloS One 6(10):e25868. doi: 10.1371\/journal.pone.0025868","journal-title":"PloS One"},{"issue":"205","key":"2333_CR14","doi-asserted-by":"crossref","first-page":"205ra134","DOI":"10.1126\/scitranslmed.3006843","volume":"5","author":"F Smaill","year":"2013","unstructured":"Smaill F, Jeyanathan M, Smieja M, Medina MF, Thanthrige-Don N, Zganiacz A, Yin C, Heriazon A, Damjanovic D, Puri L, Hamid J, Xie F, Foley R, Bramson J, Gauldie J, Xing Z (2013) A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med 5(205):205ra134. doi: 10.1126\/scitranslmed.3006843","journal-title":"Sci Transl Med"},{"issue":"5","key":"2333_CR15","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/jnci\/djj111","volume":"98","author":"K Garber","year":"2006","unstructured":"Garber K (2006) China approves world\u2019s first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 98(5):298\u2013300. doi: 10.1093\/jnci\/djj111","journal-title":"J Natl Cancer Inst"},{"issue":"47","key":"2333_CR16","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1016\/j.vaccine.2009.08.048","volume":"27","author":"X Liang","year":"2009","unstructured":"Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y (2009) Epidemiological serosurvey of hepatitis B in China\u2013declining HBV prevalence due to hepatitis B vaccination. Vaccine 27(47):6550\u20136557. doi: 10.1016\/j.vaccine.2009.08.048","journal-title":"Vaccine"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-015-2333-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00705-015-2333-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-015-2333-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T22:52:04Z","timestamp":1553640724000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00705-015-2333-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,24]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["2333"],"URL":"https:\/\/doi.org\/10.1007\/s00705-015-2333-2","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,24]]}}}